Given the relation to mosaic RASopathies involving hyperactivation of the RAS-MAPK-MEK pathway, MEK inhibitors have shown some initial promise in case reports of congenital melanocytic lesions with activating genetic variants in NRAS and mosaic BRAF fusions [18-20]. This evidence concerns the gene BRAF and RASopathy.